The Big Potential of Small Particles: Lipid-Based Nanoparticles and Exosomes in Vaccination

Shimon, Marina Ben; Shapira, Shiran; Seni, Jonathan; Arber, Nadir

doi:10.3390/vaccines10071119

Cited by 8 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the vehicle of choice for antigen delivery was found to be lipid nanoparticles. The choice of liposomes in both clinical trials and FDA-approved drugs lies in the fact that the liposomes show remarkable results due to their high bioavailability and relatively low immunogenicity [116][117][118]. In the middle of November 2020, when Moderna revealed the results of the phase 3 clinical trial of a COVID-19 vaccine preventing nearly 95% of virus infection (which was followed by a similar report published by BioNTech and Pfizer (on 18 November 2020)), the invention stirred curiosity and disbelief, while also bringing hope and optimism [96].…”

Section: Study Title Clinical Trails Gov Id Clinical Trial Interventionsmentioning

confidence: 99%

Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus

Chowdhury,

Kundu

2023

Diseases

View full text Add to dashboard Cite

The COVID-19 pandemic has had a profound impact on societies, public health, healthcare systems, and the world economy. With over 771 million people infected worldwide and a staggering death toll exceeding 6,960,783 as of 4 October 2023 (according to the World Health Organization), the urgency for a solution was paramount. Since the outbreak, the demand for immediate treatment for COVID-19 viral infection, as well as for effective vaccination against this virus, was soaring, which led scientists, pharmaceutical/biotech companies, government health agencies, etc., to think about a treatment strategy that could control and minimize this outbreak as soon as possible. Vaccination emerged as the most effective strategy to combat this infectious disease. For vaccination strategies, any conventional vaccine approach using attenuated live or inactivated/engineered virus, as well as other approaches, typically requires years of research and assessment. However, the urgency of the situation promoted a faster and more effective approach to vaccine development against COVID-19. The role of nanotechnology in designing, manufacturing, boosting, and delivering vaccines to the host to counter this virus was unquestionably valued and assessed. Several nanoformulations are discussed here in terms of their composition, physical properties, credibility, and applications in past vaccine development (as well as the possibility of using those used in previous applications for the generation of the COVID-19 vaccine). Controlling and eliminating the spread of the virus and preventing future recurrence requires a safe, tolerable, and effective vaccine strategy. In this review, we discuss the potential of nanoformulations as the basis for an effective vaccine strategy against COVID-19.

show abstract

Section: Study Title Clinical Trails Gov Id Clinical Trial Interventionsmentioning

confidence: 99%

Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus

Chowdhury,

Kundu

2023

Diseases

View full text Add to dashboard Cite

show abstract

“…Liposomes have shown great potential in cancer therapy and therapeutic agent delivery. Most recently, a majority of the successful mRNAbased COVID-19 vaccines were housed in lipid-based nanosize carriers [8,9]. While the current non-triggered release approaches in liposomal drug delivery for the complicated situation of a malignant tumor microenvironment exhibit reduced toxic profiles, some preparations remain associated with systemic drug toxicities [10].…”

Section: Introductionmentioning

confidence: 99%

Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy

Stolarz¹,

Chhetri²,

Borrelli³

et al. 2022

Preprint

View full text Add to dashboard Cite

Targeted delivery of drugs or other therapeutic agents through internal or external triggers has been used to control and accelerate the release from liposomal carriers in a number of studies, but relatively few utilize energy of therapeutic X-rays as a trigger. We have synthesized liposomes that are triggered by ionizing radiation (RTLs) to release their therapeutic payload. These liposomes are composed of natural egg PE, DSPC, cholesterol, and DSPE-PEG-2000, and the mean size of the RTL was in the range of 114 to 133 nm, as measured by NTA. The trigger mechanism is the organic halogen, chloral hydrate, which is known to generate free protons upon exposure to ionizing radiation. Once protons are liberated, a drop in internal pH of the liposome promotes destabilization of the lipid bilayer and escape of the liposomal contents. In proof of principle studies, we assessed RTL radiation-release of fluorescent tracers upon exposure to a low pH extracellular environment or exposure to X-ray irradiation. Biodistribution imaging before and after irradiation demonstrated a preferential uptake and release of the liposomes and their cargo at the site of local tumor irradiation. Finally, a potent metabolite of the commonly used chemotherapy irinotecan, SN-38, was loaded into RTL along with near infrared (NIR) fluorescent dyes for imaging studies and measuring tumor cell cytotoxicity alone or combined with radiation exposure, in vitro and in vivo. Fully loaded RTLs were found to increase tumor cell killing with radiation in vitro and enhance tumor growth delay in vivo after three i.v. injections combined with three, 5 Gy local tumor radiation exposures compared to either treatment modality alone.

show abstract

“…Liposomes have shown great potential in cancer therapy and therapeutic agent delivery. Most recently, a majority of the successful mRNA-based COVID-19 vaccines were housed in lipid-based nanosize carriers [ 8 , 9 ]. While the current non-triggered release approaches in liposomal drug delivery for the complicated situation of a malignant tumor microenvironment exhibit reduced toxic profiles, some preparations remain associated with systemic drug toxicities [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy

Stolarz

Chhetri²,

Borrelli

et al. 2022

IJMS

View full text Add to dashboard Cite

Targeted delivery of drugs or other therapeutic agents through internal or external triggers has been used to control and accelerate the release from liposomal carriers in a number of studies, but relatively few utilize energy of therapeutic X-rays as a trigger. We have synthesized liposomes that are triggered by ionizing radiation (RTLs) to release their therapeutic payload. These liposomes are composed of natural egg phosphatidylethanolamine (PE), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), cholesterol, and 1,2-disteroyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000] (DSPE-PEG-2000), and the mean size of the RTL was in the range of 114 to 133 nm, as measured by nanoparticle tracking analysis (NTA). The trigger mechanism is the organic halogen, chloral hydrate, which is known to generate free protons upon exposure to ionizing radiation. Once protons are liberated, a drop in internal pH of the liposome promotes destabilization of the lipid bilayer and escape of the liposomal contents. In proof of principle studies, we assessed RTL radiation-release of fluorescent tracers upon exposure to a low pH extracellular environment or exposure to X-ray irradiation. Biodistribution imaging before and after irradiation demonstrated a preferential uptake and release of the liposomes and their cargo at the site of local tumor irradiation. Finally, a potent metabolite of the commonly used chemotherapy irinotecan, SN-38, was loaded into RTL along with near infrared (NIR) fluorescent dyes for imaging studies and measuring tumor cell cytotoxicity alone or combined with radiation exposure, in vitro and in vivo. Fully loaded RTLs were found to increase tumor cell killing with radiation in vitro and enhance tumor growth delay in vivo after three IV injections combined with three, 5 Gy local tumor radiation exposures compared to either treatment modality alone.

show abstract

The Big Potential of Small Particles: Lipid-Based Nanoparticles and Exosomes in Vaccination

Cited by 8 publications

References 71 publications

Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus

Nanotechnology Platform for Advancing Vaccine Development against the COVID-19 Virus

Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy

Liposome Formulation for Tumor-Targeted Drug Delivery Using Radiation Therapy

Contact Info

Product

Resources

About